CLINICAL TRIALS PROFILE FOR AZILECT
✉ Email this page to a colleague
All Clinical Trials for AZILECT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00399477 ↗ | A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease | Completed | Teva Neuroscience, Inc. | Phase 4 | 2006-10-01 | Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD: - Group 1 Patients using Azilect and no other therapy. - Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or Requip. |
| NCT00696215 ↗ | The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease | Unknown status | Istanbul University | Phase 4 | 2007-06-01 | The objective of the study is to assess the effects of rasagiline on cognitive functions in patient with Parkinson's disease. Patients on any dopaminergic medications will be assigned to receive rasagiline 1 mg or placebo over 3 months. Cognitive functions will be assessed by selected neuropsychological tests representing each cognitive domain. |
| NCT00936676 ↗ | ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects | Completed | H. Lundbeck A/S | 2009-07-01 | Eligible participants, who participated in the ADAGIO trial and who sign an approved informed consent form, will be enrolled into the study at their original study locations. participants who have stopped rasagiline therapy and in the opinion of the investigator will gain clinical benefit from restarting treatment can also be considered for enrollment in the Core follow-up study period. Use of any other anti-PD treatment is permitted as deemed necessary by the treating physician (according to the participants clinical status). | |
| NCT00936676 ↗ | ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects | Completed | Teva Neuroscience, Inc. | 2009-07-01 | Eligible participants, who participated in the ADAGIO trial and who sign an approved informed consent form, will be enrolled into the study at their original study locations. participants who have stopped rasagiline therapy and in the opinion of the investigator will gain clinical benefit from restarting treatment can also be considered for enrollment in the Core follow-up study period. Use of any other anti-PD treatment is permitted as deemed necessary by the treating physician (according to the participants clinical status). | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AZILECT
Condition Name
Clinical Trial Locations for AZILECT
Trials by Country
Clinical Trial Progress for AZILECT
Clinical Trial Phase
Clinical Trial Sponsors for AZILECT
Sponsor Name
